Pharmaceutical Technology-10-02-2007

Pharmaceutical Technology

In the Spotlight October 2007

October 02, 2007

In the Spotlight

31

10

Carl Zeiss MicroImaging (Thornwood, NY) recently introduced its "Colibri" light-emitting diode (LED) light source for fluorescence microscopy. The product is "the only LED light source optimized for white-field microscopy systems," says Becky Homan, product manager for biomedical light microscopy.

Pharma Capsules

October 02, 2007

Pharma Capsules

31

10

Lancaster Laboratories (Lancaster, PA) acquired Microchem Laboratories (Waterford, Ireland). Microchem was established in 1986 and is one of Ireland's testing and research laboratories. Microchem offers microbiological, chemical, and environmental analyses to the pharmaceutical, medical-device, and chemical industries in Europe and Asia.

Sustainable Packaging Resources

October 02, 2007

Online Exclusive

31

10

When it comes to designing and sourcing sustainable packaging, there are no simple answers. Sustainable packaging depends on a complex interaction of environmental, social, and economic considerations, which are influenced by geography and other factors such as renewability, compostability, biodegradability, weight, and performance.

In the Field

October 02, 2007

In the Field

31

10

The United States House of Representatives passed its version of the Patent Reform Act of 2007 (H.R. 1908) in September in a 220-175 vote. Although the bill aims to fix current flaws in the US patent system and to bring it in line with those of other countries' systems, the biopharmaceutical industry is largely unhappy with the news, arguing that it will reduce patent protection.

The Application of Quality by Design to Analytical Methods

October 02, 2007

Peer-Reviewed Research

31

10

To monitor and control processes or products, analytical methodology must be fit for purpose. An approach to apply quality by design principles to the design and evaluation of analytical methods has therefore been developed to meet these needs. This article features a downloadable template on which to conduct a failure mode effect analysis (FMEA).

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase

October 02, 2007

Peer-Reviewed Research

31

10

The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.

We Need More Overseas Inspections

October 02, 2007

This Time Around

31

10

Offshore contracting is nothing new for the pharmaceutical industry. Neither is importing active ingredients, or prescription drugs, for that matter. But the authorities are having trouble keeping up with these growing international trends.

Strategy for the Prediction and Selection of Drug Substance Salt Forms

October 02, 2007

Peer-Reviewed Research

31

10

Through consideration of the ionic equilibria of acids and bases, one may readily calculate the formation constant of a salt species solely on the basis of knowledge of the pKA value of the acid and the pKB value of the base.

Materials of Construction Based on Recovery Data for Cleaning Validation

October 02, 2007

Peer-Reviewed Research

31

10

The material of construction is a factor in the recovery of residue in cleaning validation. An analysis of existing recovery data showed that recovery factors for drug products on various materials of construction may be categorized into several groupings.

Acceptance Limits for the New ICH USP 29 Content-Uniformity Test

October 02, 2007

Peer-Reviewed Research

31

10

Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.